Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and Lisinopril microalbuminuria (CALM) study

被引:717
作者
Mogensen, CE [1 ]
Neldam, S
Tikkanen, I
Oren, S
Viskoper, R
Watts, RW
Cooper, ME
机构
[1] Aarhus Univ Hosp, Kommunehosp, Dept Med M, DK-8000 Aarhus C, Denmark
[2] Univ Helsinki Hosp, Clin Internal Dis, FIN-00029 Helsinki, Finland
[3] Barzilai Govt Hosp, Ashqelon, Israel
[4] Univ Melbourne, Dept Med, Heidelberg West, Vic 3084, Australia
来源
BMJ-BRITISH MEDICAL JOURNAL | 2000年 / 321卷 / 7274期
关键词
D O I
10.1136/bmj.321.7274.1440
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives To assess and compare the effects of candesartan or lisinopril, or both, on blood pressure and urinary albumin excretion in patients with microalbuminuria, hypertension, and type 2 diabetes. Design Prospective, randomised, parallel group, double blind study with four week placebo run in period and 12 weeks' monotherapy with candesartan or lisinopril followed by 12 weeks' monotherapy or combination treatment Setting Tertiary hospitals and primary care centres in four countries (37 centres). Participants 199 patients aged 30-75 years. Interventions Candesartan 16 mp; once daily, lisinopril 20 mg once daily. Main outcome measures Blood pressure and urinary albumin:creatinine ratio. Results At 12 creeks mean (95% confidence interval) reductions in diastolic blood pressure were 9.5 mm Hg (7.7 mm Hg to 11.2 mm Hg, P < 0.002) and 9.7 mm Hg (7.9 mm Hg to 115 mm Hg, P < 0.001), respectively, and in urinary albumin:creatinine ratio were 30% (15% to 42%, P < 0.001) and 46% (35% to 56%, P < 0.001) for candesartan and lisinopril, respectively. At 24 weeks the mean reduction in diastolic blood pressure with combination treatment (16.3 mm Hg, 13.6 mm Hg to 18.9 mm Hg, P < 0.001) was significantly greater than that with candesartan (10.4 mm Hg, 7.7 mm Hg to 13.1 mm Hg, P < 0.001) or lisinopril (mean 10.7 mm Hg. 8.0 nun Hg to 13.5 mm Hg, P < 0.001). Furthermore, the reduction in urinary albumin:creatinine ratio with combination treatment (50%, 36% to 61%, P<0.001) was greater than with candesartan (24%, 0% to 43%, P = 0.05) and lisinopril (39%, 20% to 54%, P < 0.001). All treatments were generally well tolerated. Conclusion Candesartan 16 mg once daily is as effective as lisinopril 20 mg once daily in reducing blood pressure and microalbuminuria in hypertensive patients with type 2 diabetes. Combination treatment is well tolerated and more effective in reducing blood pressure.
引用
收藏
页码:1440 / 1444
页数:5
相关论文
共 30 条
[21]   Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria [J].
Mathiesen, ER ;
Hommel, E ;
Hansen, HP ;
Smidt, UH ;
Parving, HH .
BRITISH MEDICAL JOURNAL, 1999, 319 (7201) :24-25
[22]   Candesartan cilexetil - A review of its use in essential hypertension [J].
McClellan, KJ ;
Goa, KL .
DRUGS, 1998, 56 (05) :847-869
[23]   PREVENTION OF DIABETIC RENAL-DISEASE WITH SPECIAL REFERENCE TO MICROALBUMINURIA [J].
MOGENSEN, CE ;
KEANE, WF ;
BENNETT, PH ;
JERUMS, G ;
PARVING, HH ;
PASSA, P ;
STEFFES, MW ;
STRIKER, GE ;
VIBERTI, GC .
LANCET, 1995, 346 (8982) :1080-1084
[24]  
Parving HH, 1996, BRIT MED J, V313, P591
[25]   British Hypertension Society guidelines for hypertension management 1999: summary [J].
Ramsay, LE ;
Williams, B ;
Johnston, GD ;
MacGregor, GA ;
Poston, L ;
Potter, JF ;
Poulter, NR ;
Russell, G .
BMJ-BRITISH MEDICAL JOURNAL, 1999, 319 (7210) :630-635
[26]   Nephropathy in type 2 diabetes [J].
Ritz, E .
JOURNAL OF INTERNAL MEDICINE, 1999, 245 (02) :111-126
[27]   Safety of the combination of valsartan and benazepril in patients with chronic renal disease [J].
Ruilope, LM ;
Aldigier, JC ;
Ponticelli, C ;
Oddou-Stock, P ;
Botteri, F ;
Mann, JF .
JOURNAL OF HYPERTENSION, 2000, 18 (01) :89-95
[28]   Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy [J].
Russo, D ;
Pisani, A ;
Balletta, MM ;
De Nicola, L ;
Savino, FA ;
Andreucci, M ;
Minutolo, R .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 33 (05) :851-856
[29]   Renal effects of angiotensin I-receptor blockade and angiotensin convertase inhibition in man [J].
Schmitt, F ;
Natov, S ;
Martinez, F ;
Lacour, B ;
Hannedouche, TP .
CLINICAL SCIENCE, 1996, 90 (03) :205-213
[30]   Clinical profile of the novel angiotensin II type I blocker candesartan cilexetil [J].
Sever, PS .
JOURNAL OF HYPERTENSION, 1997, 15 :S9-S12